Bosc et al. have suggested that the resistance mechanism in cancer might be associated with a shift toward an increased OxPhos status that should be considered a distinctive characteristic of drug resistance.30 The master PGC-1/ERR axis that controls mitochondrial OxPhos activity should be considered as a new pathway that drives resistance in tumor progression. This evidence concerns the gene PPARGC1A and cancer.